What's Happening?
Kessler Topaz Meltzer & Check, LLP (KTMC) has announced a securities fraud class action lawsuit against Soleno Therapeutics, Inc. The lawsuit pertains to alleged material misstatements and omissions related to Soleno's Phase 3 clinical trial program for
diazoxide choline extended-release tablets (DCCR), used for treating hyperphagia in individuals with Prader-Willi syndrome. The class period for the lawsuit is from March 26, 2025, to November 4, 2025. Investors who purchased Soleno common stock during this period and incurred losses are encouraged to contact KTMC for potential recovery options. The lawsuit claims that Soleno misrepresented safety concerns and commercial viability of DCCR, leading to a significant drop in stock price following a report by Scorpion Capital, LLC, which highlighted issues in the clinical trial program.
Why It's Important?
This lawsuit is significant as it highlights potential corporate governance and transparency issues within Soleno Therapeutics, which could impact investor confidence and the company's market reputation. The allegations of misrepresentation and safety concerns could lead to regulatory scrutiny and affect the commercial success of DCCR. For investors, the outcome of this lawsuit could influence financial recovery and future investment decisions. The case also underscores the importance of accurate and transparent communication from pharmaceutical companies regarding clinical trials, as these disclosures directly affect investor trust and market performance.
What's Next?
Investors have until May 5, 2026, to seek lead plaintiff status in the class action. The lead plaintiff will represent the class in directing the litigation and selecting counsel. The outcome of this lawsuit could lead to financial recovery for affected investors and potentially influence Soleno's business practices and regulatory compliance. The case may also prompt other investors to scrutinize pharmaceutical companies' disclosures more closely, potentially leading to broader industry changes in transparency and accountability.
